How are comorbidities for RA patients managed outside of rheumatology? A recent Canadian study developed and assessed quality measures related to preventive care and screenings for RA patients in a primary care setting, comparing RA and non-RA patients. The results: Primary care physicians often provide similar levels of care to patients with and without RA. But RA patients were less likely to receive some cancer screenings and all necessary tests to assess their cardiovascular risk…
Insights into Precision Immunology for Research, RA & Infection
Research in precision immunology is in its early stages. But new insights into cohorts, RA gene expression and infection presented at FOCUS 2017 may benefit future research and patient care…
AMP RA/Lupus Network Shares Its Progress
Researchers from the AMP RA/Lupus Network came together in June at the annual FOCIS meeting to share their progress as they perform a systematic molecular deconstruction of human diseases…
Reassuring Data on Cancer Risk with Contemporary RA Drugs
NEW YORK (Reuters Health)—A large Swedish study1 provides reassuring data on the risk of cancer in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF) inhibitors or with tocilizumab, abatacept or rituximab. Overall, the risk of malignant neoplasms did not differ between patients treated with a first anti-TNF drug; a second anti-TNF drug; tocilizumab,…
FDA Update: Biosiomilar to Adalimumab Receives FDA Approval
The FDA has approved adalimumab-adbm, a biosimilar, to treat multiple chronic inflammatory diseases…
Opioid Use in U.S. RA Patients
Nationally, opioid use and addiction are drawing increased scrutiny. An increase in the number of overdoses and addiction to heroin and prescription pain relievers in the past decade has been attributed in part to increased prescribing of opioids for the treatment of pain by physicians. National trends suggest the rate of opioid prescribing plateaued in…
Switching from Bisphosphonates to Teriparatide May Improve BMD in Women with RA
NEW YORK (Reuters Health)—Switching women with rheumatoid arthritis (RA) from oral bisphosphonates to teriparatide increases bone mineral density (BMD) and trabecular bone score, according to a new report. Researchers in Japan conducted an 18-month observational study of more than 175 women with RA (mean age: 66) who remained on oral bisphosphonates, switched to denosumab (DMAb),…
Some Jobs Tied to Higher Risk of RA
(Reuters Health)—Workers exposed to airborne toxins may have an elevated risk of developing rheumatoid arthritis (RA), an immune system disorder that causes debilitating swelling and pain in the joints, a Swedish study suggests. Among men, bricklayers, concrete workers and electricians had at least twice the risk of RA they would have in certain other occupations,…
Sirukumab Approval Stalls
Citing safety concerns, the FDA Arthritis Advisory Committee voted against recommending approval of sirukumab for treating adults with RA…
TNF Stabilizes Inflammatory RNA in Synoviocytes
A recent study has helped researchers gain insight into the genome-wide regulation of mRNA stability in RA fibroblast-like synoviocytes (FLS). Chronic exposure of FLS to tumor necrosis factor appears to increase mRNA stability, enhancing the expression of inflammatory genes and the perpetuation of synovitis…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 30
- Next Page »